Top

Published in:

Open Access 01-12-2013 | Original investigation

Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans

Authors: Katja Piotrowski, Melanie Becker, Julia Zugwurst, Ingeborg Biller-Friedmann, Gerald Spoettl, Martin Greif, Alexander W Leber, Alexander Becker, Rüdiger P Laubender, Corinna Lebherz, Burkhard Goeke, Nikolaus Marx, Klaus G Parhofer, Michael Lehrke

Published in: Cardiovascular Diabetology | Issue 1/2013

Abstract

Background

GLP-1 is an incretine hormone which gets secreted from intestinal L-cells in response to nutritional stimuli leading to pancreatic insulin secretion and suppression of glucagon release. GLP-1 further inhibits gastric motility and reduces appetite which in conjunction improves postprandial glucose metabolism. Additional vasoprotective effects have been described for GLP-1 in experimental models. Despite these vasoprotective actions, associations between endogenous levels of GLP-1 and cardiovascular disease have yet not been investigated in humans which was the aim of the present study.

Methods

GLP-1 serum levels were assessed in a cohort of 303 patients receiving coronary CT-angiography due to typical or atypical chest pain.

Results

GLP-1 was found to be positively associated with total coronary plaque burden in a fully adjusted model containing age, sex, BMI, hypertension, diabetes mellitus, smoking, triglycerides, LDL-C (low density lipoprotein cholesterol), hsCRP (high-sensitive C-reactive protein), and eGFR (estimated glomerular filtration rate) (OR: 2.53 (95% CI: 1.12 – 6.08; p = 0.03).

Conclusion

Circulating GLP-1 was found to be positivity associated with coronary atherosclerosis in humans. The clinical relevance of this observation needs further investigations.

Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I: Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011, 364 (9): 829-841.CrossRefPubMed

Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A: HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care. 2002, 25 (7): 1135-1141. 10.2337/diacare.25.7.1135.CrossRefPubMed

Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C: Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011, 343: d4169-10.1136/bmj.d4169.PubMedCentralCrossRefPubMed

Lehrke M, Marx N: Cardiovascular effects of incretin-based therapies. Rev Diabet Stud. 2011, 8 (3): 382-391. 10.1900/RDS.2011.8.382.PubMedCentralCrossRefPubMed

Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007, 132 (6): 2131-2157. 10.1053/j.gastro.2007.03.054.CrossRefPubMed

Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001, 50 (3): 609-613. 10.2337/diabetes.50.3.609.CrossRefPubMed

Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V: Attenuated GLP-1 secretion in obesity: cause or consequence?. Gut. 1996, 38 (6): 916-919. 10.1136/gut.38.6.916.PubMedCentralCrossRefPubMed

Vaag AA, Holst JJ, Volund A, Beck-Nielsen HB: Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)–evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol. 1996, 135 (4): 425-432. 10.1530/eje.0.1350425.CrossRefPubMed

Calanna S, Christensen M, Holst JJ, Laferrere B, Gluud LL, Vilsboll T, Knop FK: Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 2013, 56 (5): 965-972. 10.1007/s00125-013-2841-0. Epub 2013 Feb 3PubMedCentralCrossRefPubMed

10.

Yamaoka-Tojo M, Tojo T, Takahira N, Matsunaga A, Aoyama N, Masuda T, Izumi T: Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol. 2010, 9: 17-10.1186/1475-2840-9-17.PubMedCentralCrossRefPubMed

11.

Broedl UC, Lebherz C, Lehrke M, Stark R, Greif M, Becker A, von Ziegler F, Tittus J, Reiser M, Becker C: Low adiponectin levels are an independent predictor of mixed and non-calcified coronary atherosclerotic plaques. PLoS One. 2009, 4 (3): e4733-10.1371/journal.pone.0004733.PubMedCentralCrossRefPubMed

12.

Monami M, Cremasco F, Lamanna C, Colombi C, Desideri CM, Iacomelli I, Marchionni N, Mannucci E: Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res. 2011, 2011: 215764.PubMedCentralPubMed

13.

Monami M, Ahren B, Dicembrini I, Mannucci E: Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013, 15 (2): 112-120. 10.1111/dom.12000.CrossRefPubMed

14.

Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R: Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation. 2011, 124 (21): 2338-2349. 10.1161/CIRCULATIONAHA.111.041418.PubMedCentralCrossRefPubMed

15.

Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A: Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol. 2012, 11: 107-10.1186/1475-2840-11-107.PubMedCentralCrossRefPubMed

16.

Li CJ, Li J, Zhang QM, Lv L, Chen R, Lv CF, Yu P, Yu DM: Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity. Cardiovasc Diabetol. 2012, 11: 142-10.1186/1475-2840-11-142.PubMedCentralCrossRefPubMed

17.

Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ: Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol. 2012, 11: 64-10.1186/1475-2840-11-64.PubMedCentralCrossRefPubMed

18.

Gupta NA, Kolachala VL, Jiang R, Abramowsky C, Romero R, Fifadara N, Anania F, Knechtle S, Kirk A: The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis. Am J Pathol. 2012, 181 (5): 1693-1701. 10.1016/j.ajpath.2012.07.015.CrossRefPubMed

19.

Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, Eppler E, Bouzakri K, Wueest S, Muller YD: Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med. 2011, 17 (11): 1481-1489. 10.1038/nm.2513.PubMedCentralCrossRefPubMed

20.

Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS, Smith JP, Milionis HJ, Douglas KM, Nightingale P, Kitas GD: Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis. 2009, 204 (1): 178-183. 10.1016/j.atherosclerosis.2008.08.036.CrossRefPubMed

21.

Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B: Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes. 2004, 53 (3): 654-662. 10.2337/diabetes.53.3.654.CrossRefPubMed

22.

Orskov C, Andreasen J, Holst JJ: All products of proglucagon are elevated in plasma from uremic patients. J Clin Endocrinol Metab. 1992, 74 (2): 379-384. 10.1210/jc.74.2.379.PubMed

23.

Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D: Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab. 2009, 94 (6): 1843-1852. 10.1210/jc.2008-1296.PubMedCentralCrossRefPubMed

24.

Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007, 298 (3): 309-316. 10.1001/jama.298.3.309.CrossRefPubMed

Title: Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans
Authors: Katja Piotrowski
Melanie Becker
Julia Zugwurst
Ingeborg Biller-Friedmann
Gerald Spoettl
Martin Greif
Alexander W Leber
Alexander Becker
Rüdiger P Laubender
Corinna Lebherz
Burkhard Goeke
Nikolaus Marx
Klaus G Parhofer
Michael Lehrke
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Cardiovascular Diabetology / Issue 1/2013
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/1475-2840-12-117

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2013

Sagittal abdominal diameter is a more independent measure compared with waist circumference to predict arterial stiffness in subjects with type 2 diabetes - a prospective observational cohort study

Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study

Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study

Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes

Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal women

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials